Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Publicity for sports supplement programs

This article was originally published in The Tan Sheet

Executive Summary

The dietary supplement industry "is doing a horrible job" of getting information out about its self-regulatory efforts, notes Jon Benninger at the Food and Drug Law Institute's dietary supplement emerging issues and trends conference Jan. 29 in Washington. Benninger, director of business development for Virgo Publishing, recounts how the CEO of U.S. Track and Field had discouraged use of all supplements by the group's athletes and was unaware of programs that screen supplement products tailored to professional athletes. Such programs include the Athletic Banned Substances Certification Program and a separate certification initiative specifically for National Football League players, both run by NSF International (1"The Tan Sheet" Jan. 21, 2008, p. 7). While such programs are admirable, Benninger says it remains up to industry to publicize the efforts

You may also be interested in...



NSF Expands Sports Product Testing, Appoints GM At “Crucial Time”

NSF International appointed Edward Wyszumiala Jan. 14 to head the organization's supplement programs as it expands its testing of sports nutrition products for banned substances in response to growing concern about adulterated products

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102593

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel